Biohaven To Present Data On BHV-1530, FGFR3-Directed ADC Using Topoisomerase I Payload, At 38th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics

Biohaven Ltd. announced that data on its FGFR3-directed antibody-drug conjugate, BHV-1530, will be presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics from November 18-20, 2026. The Phase 1 findings from the ongoing BHV1530-101 study indicate early clinical activity and a favorable safety profile, with no dose-limiting toxicities reported. Additionally, Biohaven has begun enrolling patients for a study evaluating BHV-1530 in combination with Regeneron's cemiplimab (Libtayo).